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TO THE EDITOR
BRAF (B-rat fibrosarcoma) inhibitors are
standard treatment for BRAF-mutated
metastasized melanoma, among which
vemurafenib and dabrafenib have
been approved. Although these are very
well tolerated (Chapman et al., 2011;
Hauschild et al., 2012; Sosman et al.,
2012), cutaneous side effects are com-
mon, including UV sensitivity, exan-
themas, keratosis pilaris, palmoplantar
hyperkeratosis, and verrucous skin
tumors (Chu et al., 2012). Squamous
cell carcinoma (SCC)—mainly of the
keratoacanthoma type—can also deve-
lop, usually approximately 2 months
after the start of BRAF inhibitor treat-
ment (Flaherty et al., 2010). HRAS
mutations have been observed in 21–
60% of cases, with HRAS Q61L being
the most frequent (Anforth et al., 2012;
Oberholzer et al., 2012; Su et al., 2012).
It has been postulated that mutated
HRAS promotes tumor growth from
preexisting lesions as a result of para-
doxical activation of mitogen-activated
protein kinase (MAPK) signaling during
treatment with BRAF inhibition (Su
et al., 2012; Kulkarni et al., 2013).
Because the verrucous lesions resem-
ble warts, both clinically and histologi-
cally, involvement of human papilloma
virus (HPV) has been discussed,
although association with HPV could
not be demonstrated (Ganzenmueller
et al., 2013). To address a possible
pathogenetic role of HRAS mutations
in benign BRAF inhibitor–associated
tumors, we analyzed 42 samples from
15 patients (after written informed con-
sent, ethical approval S-091/2011) for
the presence of RAS mutations using a
SNaPshot assay as reported previously
(Groesser et al., 2013) after DNA was
isolated from microdissected paraffin-
embedded tissue samples of patients
from the Department of Dermatology
and National Center for Tumor Dis-
eases, University Hospital Heidelberg.
Seven SCC samples from the same pati-
ents served as a control. In addition,
samples were stained for pAkt, pERK,
p16, and p21 immunohistochemically
and scored with the H-Score in negative
( ) to strongly positive (þ þ þ )
samples.
The 42 benign skin lesions were
identified histologically as verrucous
acanthomas (n¼ 33), flat acanthomas
(n¼ 4), acantolytic (warty) dyskeratomas
(n¼ 2), fibromas (n¼2), and seborrhoic
keratosis (n¼1; Figure 1). RAS muta-
tions were detected in 28 of 42 (67%) of
these benign skin lesions (Table 1). Most
of the mutations (25/28; 89%) affected
the HRAS gene, whereas only three
benign lesions harbored a KRAS muta-
tion. The most frequent HRAS mutation
was Q61L, which was found in 17/25
(68%) lesions with a HRAS mutation.
There was no strong correlation bet-
ween the mutation and the type of skin
lesion. For example, verrucous acan-
thoma was associated with several dif-
ferent HRAS mutations and with a KRAS
mutation. Some of the patients revealed
an SCC in addition to the benign
lesions. In total, 5/7 SCCs included
in this study showed a RAS mutation
(4 HRAS, 1 KRAS). The mutational
spectrum was not significantly different
between the benign and malignant
epithelial tumors. The factors determin-
ing a distinct morphology and dignity
of the lesions in the setting of the
same RAS mutation are unknown, but
additional genetic alterations might
have a role. Microscopically, most of
the benign HRAS-mutated skin lesions
resembled verrucous acanthomas
(n¼ 27; 96.4%). Only one mutation-
positive sample had a different appear-
ance and was diagnosed as a flat
acanthoma (n¼1; 3.6%). For the RAS
wild-type samples (33% in this study),
histologic diagnoses varied with only six
verrucous acanthomas and others like
flat acanthoma (n¼3), acantholytic dys-
keratoma (n¼2), fibroma (n¼2), and
seborrhoic keratosis (n¼1; Figure 1).
One can speculate whether these
benign lesions harbor other activating
mutations in the Ras-Raf-MAPK path-
way or may have arisen coincidently
during BRAF inhibitor treatment without
a pathogenic link to the drug. Anforth
et al. (2012), e.g., describe a PIK3CA
mutation in a Ras wild-type verrucal
keratosis under Dabrafenib treatment.
Interestingly, the proportion of RAS-
mutated lesions in the benign
verrucous acanthomas (27/33, 81.8%)
was even higher than that reported in
SCC (Anforth et al., 2012; Oberholzer
et al., 2012; Su et al., 2012). This goes
in line with a smaller previous investi-
gation of 11 benign verrucous lesions,
which revealed a RAS mutation
frequency of 63.6% (Anforth et al.,
2012).
Immunohistochemically, only a weak
staining could be seen for pERK and
pAkt, which did not differ significantly
between benign and malignant samples
(Fisher’s exact test: P¼0.546 for pAkt,
no staining differences for pERK) and
only marginally between Ras-mutated
and wild-type samples, with a trend to
more pAkt in mutated samples (Fisher’s
exact test: P¼ 0.078, Figure 2). Expres-
sion of the cell cycle control proteins
p16 and p21 differed remarkably bet-
ween the samples but not significantly
between benign and malignant lesions
based on histologic morphology (Fish-
er’s exact test: P¼0.311 for p16;
P¼0.463 for p21). Hence, no loss of
these CDK inhibitors was found in the
malignant lesions, which could explain
the different histologic morphology. ThisAccepted article preview online 14 August 2014; published online 11 September 2014
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is supported by previous investigations
in which p21 expression was heteroge-
nous and did not correlate with tumor
differentiation of cutaneous SCC (Lu
et al., 1999) or aggressiveness of oral
SCC (Perez-Sayans et al., 2013), likely
because complete loss of p21
expression promotes cell death in
response to stress (Warfel and El-Deiry,
2013). However, we detected remark-
able differences between RAS-mutated
and RAS wild-type samples in p21
nuclear staining, with a significantly
higher expression level in mutated
samples (Fisher’s exact test: P¼ 0.539
for p16; P¼0.006 for p21; Figure 2).
This could be explained by the fact that
p21 can, in addition to its role as a
mediator of cell cycle arrest, promote
proliferation in response to oncogenic
signaling pathways (Warfel and El-
Deiry, 2013).
Our results suggest that the pathogen-
esis of benign acanthomas and SCCs
under BRAF inhibition is similar—
initiation of proliferation in HRAS-
mutated BRAF wild-type keratinocytes
as a result of BRAF inhibition. This is
supported by results from a mouse
model of HRAS Q61L–mediated skin
carcinogenesis in which vemurafenib
accelerated the growth of lesions har-
boring HRAS mutations (Su et al., 2012).
It could therefore be speculated that
growth of benign verrucous lesions is
promoted in the same way. Impor-
tantly, it emphasizes that the mutation
itself is not oncogenic. HRAS mutations









Figure 1. Mutation analysis of benign skin lesions associated with BRAF (B-rat fibrosarcoma) inhibition in melanoma patients. (a) Clinical, (b) histologic, and
(c) genetic data of an HRAS-mutated benign verrucous acanthoma (patients 1 and 7, Table 1). The RAS SNaPshot multiplex assay chromatograms show the HRAS

















Figure 2. Example stainings of mutated and wild-type (wt) benign tumors for pAkt, p16, and p21.
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Table 1. Analysis of RAS mutations and p21 immunohistochemistry
Patient ID Histologic diagnosis RAS mutation p21 Tumor location
1 Verrucous acanthoma HRAS G12Da þ þ CSD
Verrucous acanthoma HRAS Q61L þ þ CSD
Verrucous acanthoma HRAS G12D þ þ CSD
Verrucous acanthoma KRAS G12V þ CSD
Warty dyskeratoma wt þ þ CSD
Flat akanthoma wt þ CSD
2 SCC HRAS G13R þ þ Non-CSD
Flat akanthoma HRAS Q61L þ þ Non-CSD
3 Fibroma wt þ Non-CSD
Verrucous acanthoma KRAS G12D þ CSD
4 Verrucous acanthoma HRAS Q61L þ þ Non-CSD
5 Verrucous acanthoma HRAS Q61L þ CSD
Verrucous acanthoma HRAS Q61L þ Non-CSD
Verrucous acanthoma HRAS Q61L þ Non-CSD
Verrucous acanthoma HRAS G13R þ Non-CSD
SCC HRAS Q61L þ Non-CSD
Verrucous acanthoma HRAS G13R þ þ Non-CSD
6 Verrucous acanthoma wt þ Non-CSD
7 Verrucous acanthoma HRAS Q61La þ þ CSD
Verrucous acanthoma HRAS Q61L þ þ CSD
Verrucous acanthoma HRAS Q61L þ þ CSD
Verrucous acanthoma HRAS Q61L þ þ Non-CSD
Verrucous acanthoma HRAS Q61L þ þ Non-CSD
Verrucous acanthoma HRAS Q61L þ þ Non-CSD
Verrucous acanthoma HRAS G12D þ þ CSD
8 Verrucous acanthoma HRAS G12V þ CSD
SCC HRAS G12D þ CSD
SCC wt þ CSD
SCC KRAS G12D þ þ CSD
Flat acanthoma wt þ CSD
Verrucous acanthoma wt þ þ CSD
SCC HRAS G12D þ þ CSD
SCC wt þ CSD
9 Verrucous acanthoma wt þ CSD
Verrucous acanthoma HRAS Q61L þ Non-CSD
10 Verrucous acanthoma HRAS G12D þ þ Non-CSD
Fibroma wt  CSD
Verrucous acanthoma wt þ CSD
Verrucous acanthoma KRAS G12D þ Non-CSD
Verrucous acanthoma HRAS Q61L þ Non-CSD
11 Verrucous acanthoma HRAS Q61L þ þ CSD
Verrucous acanthoma HRAS Q61L þ þ CSD
12 Warty dyskeratoma wt þ CSD
13 Verrucous acanthoma HRAS G12S þ CSD
Verrucous acanthoma wt þ Non-CSD
Verrucous acanthoma wt þ Non-CSD
14 Flat acanthoma wt  Non-CSD
Seborrheic keratosis wt þ CSD
15 Verrucous acanthoma HRAS Q61L þ CSD
Abbreviations: CSD, chronically sun-damaged skin; SCC, squamous cell carcinoma; wt, wild type.
aBenign skin lesions of Figure 1.
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keratoses and epidermal nevi, benign
lesions that lack significant malignant
potential (Groesser et al., 2012; Hafner
et al., 2012; Hafner and Groesser,
2013). Interestingly, the BRAF inhi-
bitor–mediated pathway activation
appears to be reversible because the
verrucous lesions often disappear in
patients when the BRAF inhibitor treat-
ment has to be stopped for another
reason. The benign and malignant
epithelial tumors also occur less fre-
quently during combined BRAF and
MAPK/ERK kinase inhibitor treatment
(Flaherty et al., 2012).
Not definitively answered is the ques-
tion of viral involvement––e.g., by
HPV. In line with Harvey et al. (2012)
but in contrast with Chu et al. (2012),
we have seen histological changes—
e.g., koilocytes, as seen in common viral
warts—suggesting a possible viral con-
tribution to the pathogenesis. Expression
of p16 is known to be the most
significant marker for detecting a high-
risk HPV infection—mainly HPV16 in
vulvar intraepithelial neoplasia and
neoplasia of the cervix (Santegoets
et al., 2012; Kazlouskaya et al., 2013).
We did not find any oncogenic HPV by
an E6-based PCR in six investigated
samples, three of them showing strong
cytoplasmic p16 expression (data not
shown). This goes in line with a very
recent publication in which only 13%
of cutaneous tumors under vemu-
rafenib treatment were HPV positive
(Holderfield et al., 2014).
To summarize, we demonstrate
the very frequent incidence of HRAS
mutations not only in malignant but also
in benign epithelial tumors arising
during BRAF inhibitor treatment. The
differential mechanisms that determine
the different tumor types in the setting of
a RAS mutation and BRAF inhibition
have still to be determined.
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